Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 Stocks With Easy 8-20% Gains.

Relay Therapeutics extended its winning streak to a third consecutive day on Thursday, jumping 16.43 percent to finish at $12.54 apiece, as investors gobbled up shares ahead of business updates for its cancer treatment, Zovegalisib.

In a statement on the same day, Relay Therapeutics Inc. (NASDAQ:RLAY) said that it would present updated initial data from its clinical trial at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in Philadelphia from May 19 to 22, 2026. The results covered the study of the drug on 20 efficacy-evaluable enrolled patients.

Last month, Relay Therapeutics Inc. (NASDAQ:RLAY) said that zovegalisib, in combination with fulvestrant, maintained “robust efficacy” at the recommended Phase 3 dose of 400 mg twice a day, taken with food.

Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update

“These results further support our decision to advance this regimen into the ongoing Phase 3 ReDiscover-2 trial and reinforce our confidence in selectively targeting PI3Kα mutations as a potentially differentiated approach for CDK4/6-experienced patients,” said Relay Therapeutics Inc. (NASDAQ:RLAY) President of Research and Development Don Bergstrom.

Zovegalisib is an investigational, orally administered, selective inhibitor designed to treat patients with HR+, HER2- breast cancer with a PI3Kα mutation, as well as those suffering from vascular anomalies driven by a PI3Kα mutation.

While we acknowledge the risk and potential of RLAY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RLAY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.